Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy

被引:1
|
作者
Wan, Xiaofeng [1 ]
Chen, Chuanrong [2 ]
Zhan, Jianmin [1 ]
Ye, Shuke [1 ]
Li, Runsheng [1 ]
Shen, Ming [1 ]
机构
[1] Shanghai Inst Biomed & Pharmaceut Technol, Natl Hlth Commiss NHC, Key Lab Reprod Regulat, Shanghai, Peoples R China
[2] Yijishan Hosp, Dept Oncol, Wannan Med Coll, Wuhu, Peoples R China
基金
中国国家自然科学基金;
关键词
dendritic polylysine; siRNA delivery; tumor microenvironment sensitivity; drug resistance; triple-negative breast cancer; EXTRACELLULAR PH; RESISTANCE; AXL; SYSTEM; TUMORS;
D O I
10.3389/fbioe.2024.1415191
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Drug resistance is common in triple-negative breast cancer (TNBC) therapy. To identify a method to overcome chemotherapy resistance in TNBC cells, an siRNA targeting the AXL gene (siAXL), which can overcome drug resistance, was used in this study. A nanodelivery system was constructed to co-deliver siAXL and paclitaxel (PTX).Methods: A biodegradable and tumor microenvironment (TME)-sensitive mPEG-coated dendritic polylysine material (PDPLL) was synthesized. This material was used to construct single-molecule nanoparticles to co-deliver PTX and siAXL. The drug encapsulation and morphological properties of the nanoparticles (NPs) were characterized. The sensitivity of the NPs to the TME was evaluated in vitro with a dialysis method. The tumor-targeting effect of the PDPLL NPs was evaluated by fluorescence imaging and drug distribution evaluation in vivo. The ability to overcome drug resistance was evaluated using PTX-resistant 4T1 cells (4T1/PTX cells) in both in vitro and in vivo models.Results: PDPLL NPs had a particle size of 49.6 +/- 5.9 nm and a zeta potential of 7.87 +/- 0.68 mV. The PTX drug loading (DL)% was 2.59%. The siAXL DL was 2.5 mg PDPLL: 10 nmol siAXL. The release of PTX showed sustained release performance. The release of siAXL showed sensitivity for the TME. The NPs were stable in the plasma. The NPs promoted cell uptake by PTX-resistant 4T1 cells (4T1/PTX) and promoted tumor targeting and permeability in vivo. siAXL enhanced the toxicity and apoptosis efficiency of PTX in 4T1/PTX cells, as well as the cycle arrest efficiency caused by PTX. The NPs improved the above effects. In mouse 4T1/PTX orthotopic tumors, the NPs enhanced the sensitization of PTX to siAXL.Conclusion: The PDPLL NP co-delivery system possesses good encapsulating potential not only for PTX but also for siRNA. It can enhance the tumor-targeting effect and overcome the drug resistance of 4T1/PTX both in vitro and in vivo. This system is a potential delivery system for RNAs.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
    Isakoff, Steven J.
    CANCER JOURNAL, 2010, 16 (01): : 53 - 61
  • [42] Platinum-based chemotherapy in triple-negative breast cancer
    Villarreal-Garza, C. M.
    Clemons, M.
    Kassam, F.
    Enright, K.
    Verma, S.
    Myers, J. A.
    Dent, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Post-adjuvant chemotherapy for triple-negative breast cancer
    Sun, Shanping
    Zhao, Yijun
    Xu, Kun
    MEDICAL HYPOTHESES, 2016, 90 : 74 - 75
  • [44] Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides
    Yen, Chi-Feng
    Lam, Hung-Bun
    JAMA DERMATOLOGY, 2016, 152 (11) : 1281 - 1282
  • [45] Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer
    McArthur, Heather
    ONCOLOGY-NEW YORK, 2019, 33 (04): : 137 - 140
  • [46] Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer
    Stover, Daniel G.
    Bell, Caitlin F.
    Tolaney, Sara M.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (03) : 6 - 12
  • [47] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    Cortes, J.
    Rugo, H. S.
    Cescon, D. W.
    Im, S-A
    Yusof, M. M.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V
    Pan, W.
    Schmid, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 217 - 226
  • [48] Biodegradable PEG-PCL Nanoparticles for Co-delivery of MUC1 Inhibitor and Doxorubicin for the Confinement of Triple-Negative Breast Cancer
    Akanksha Behl
    Subhash Solanki
    Shravan K. Paswan
    Tirtha K. Datta
    Adesh K. Saini
    Reena V. Saini
    Virinder S. Parmar
    Vijay Kumar Thakur
    Shashwat Malhotra
    Anil K. Chhillar
    Journal of Polymers and the Environment, 2023, 31 : 999 - 1018
  • [49] Biodegradable PEG-PCL Nanoparticles for Co-delivery of MUC1 Inhibitor and Doxorubicin for the Confinement of Triple-Negative Breast Cancer
    Behl, Akanksha
    Solanki, Subhash
    Paswan, Shravan K.
    Datta, Tirtha K.
    Saini, Adesh K.
    Saini, Reena, V
    Parmar, Virinder S.
    Thakur, Vijay Kumar
    Malhotra, Shashwat
    Chhillar, Anil K.
    JOURNAL OF POLYMERS AND THE ENVIRONMENT, 2023, 31 (03) : 999 - 1018
  • [50] Pembrolizumab plus chemotherapy in triple-negative breast cancer Reply
    Cortes, Javier
    Rugo, Hope S.
    Guo, Zifang
    Karantza, Vassiliki
    Schmid, Peter
    LANCET, 2021, 398 (10294): : 24 - 25